<DOC>
	<DOC>NCT00556127</DOC>
	<brief_summary>The purpose of this trial was to evaluate efficacy and safety of adding Rituximab to dose-dense and High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as first line treatment in young patients with DLBCL at Intermediate-High and High risk aaIPI score</brief_summary>
	<brief_title>Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>previously untreated aggressive Bcell lymphoma (Diffuse Large BCell, Primary Mediastinal, Follicular grade III b Lymphoma); age 18 to 60; IIIIV Ann Arbor stage; 02 Eastern Cooperative Oncology Group (ECOG) performance status (PS); intermediatehigh (IH) and high (H) risk score according to ageadjusted International Prognostic Index (IPI). Patients with Primary Mediastinal Lymphoma were included only if they had advanced stage III or IV disease. HIV, hepatitis B or C virus seropositivity; CNS involvement at diagnosis; abnormal renal, pulmonary and hepatic function; left ventricular ejection fraction less than 45%; pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Large B-cell Lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>ASCT</keyword>
</DOC>